Loading...
Market
Market reaction to Roche-Ascidian partnership announcement by June 30, 2024?
3
Resolution / Starting Odds
Stock increases by over 5% • 33%
Stock remains within +/- 5% • 34%
Stock decreases by over 5% • 33%
Stock market data from Nasdaq or NYSE for Roche's stock
Story
Roche Partners with Ascidian Therapeutics for $1.8B RNA Editing Deal Targeting Neurological Diseases
Jun 18, 2024, 12:53 PM
Swiss drugmaker Roche has announced a collaboration with Boston-based biotech startup Ascidian Therapeutics to develop RNA editing-based gene therapies targeting difficult-to-treat neurological diseases. Roche will pay Ascidian $42 million upfront, with the potential for up to $1.8 billion in research and development and commercial milestones. This partnership marks Roche's deeper foray into RNA therapeutics, focusing on exon editing rather than DNA modification. The collaboration aims to leverage Ascidian's RNA exon editing technology and Roche's next-generation CNS delivery capabilities. The deal is a significant step in the field of RNA writing.
View original story
Similar markets
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Positive • 25%
Neutral • 25%
Negative • 25%
Mixed • 25%
Roche outperforms Merck • 25%
Merck outperforms Roche • 25%
Both perform similarly • 25%
Both underperform the market • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%